Allergan in AD deal after calling off Pfizer merger

Less than a day after Allergan plc (NYSE:AGN) and Pfizer Inc. (NYSE:PFE) called off their proposed merger, Allergan obtained rights to a portfolio of muscarinic agonists from the Heptares Therapeutics Ltd. subsidiary of Sosei

Read the full 349 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE